On the heels of a production-tinged executive order earlier this month, the Trump administration is doubling down on efforts ...

Pfizer and RemeGen's HER2 antibody-drug conjugate delivered positive phase 3 results in a bladder cancer trial in China. | ...

One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving ...

WuXi Biologics is giving CDMO Terumo the keys to its site in Leverkusen, Germany, with a 150 million euros ($167 million) ...

With two concurrent FDA approvals, Incyte’s PD-1 inhibitor Zynyz has redeemed itself in anal cancer four years after an ...

A kidnapped child, a husband with a double life, a treacherous murder plot unraveled when the police arrive at the perfect ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. | Under a mutual agreement with ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

President Donald Trump put the pharmaceutical industry on notice early Monday with the signing of his "most favored nation" ...

Six years after Merck bought out Peloton Therapeutics, the New Jersey drugmaker is not remaining stationary with the crown ...

So far in his second term, President Donald Trump has been trying to coerce international corporations to bolster their ...

Add Sanofi to the list of drugmakers committing billions to bolster their operations in the United States as President Donald ...